Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 48
HOS-109004 · Präparat HOS-093083
(inhibition of CYP3A enzymes) HIV CCR5 – antagonist Maraviroc Maraviroc: The dose of maraviroc should be AUC: ↑ 295% decreased to 150 mg twice daily Cmax: ↑ 97% during co-administration with Kaletra Due to CYP3A inhibition by 400/100 mg twice daily. lopinavir/ritonavir. Integrase inhibitor Raltegravir Raltegravir: No dose adjustment necessary AUC: ↔ Cmax: ↔ C12: ↓ 30% Lopinavir: ↔ Co-administration with other HIV protease inhibitors (PIs) According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended. Fosamprenavir/ Fosamprenavir: Co-administration of increased doses ritonavir (700/100 mg Amprenavir concentrations are of fosamprenavir (1400 mg BID) BID) significantly reduced. with Kaletra oral solution (533/133 mg BID) to protease inhibitor-experienced patients
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) maraviroc (HOS-086186) amprenavir (HOS-086183) raltegravir (HOS-086187) fosamprenavir (HOS-086182)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage f782d1ab1c57001581096637b1440b57b3cb9dd3d00bfd730e7f8085e3a57bae · Zeichen 5188–6569 im Abschnitt